By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Gabapentinoid > Pregabalin

Pregabalin

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|620 words

Pregabalin: Drug Profile and Safety Information

What is Pregabalin?

Pregabalin is a prescription medication belonging to a class of drugs called gabapentinoids, which are anticonvulsants that also treat nerve pain. It is primarily used to manage neuropathic pain, epilepsy, and anxiety disorders. Pregabalin works by reducing abnormal electrical activity in the brain and nervous system that can cause seizures and pain signals.

Uses

Pregabalin is approved for several medical conditions:

  • Diabetic peripheral neuropathy: Treats nerve pain in the hands and feet caused by diabetes-related nerve damage
  • Postherpetic neuralgia: Manages persistent pain following shingles infections
  • Partial seizures: Used as add-on therapy to control certain types of epileptic seizures in adults
  • Fibromyalgia: Helps reduce widespread muscle pain and tenderness associated with this chronic condition
  • Generalized anxiety disorder: Approved in some countries for treating chronic anxiety symptoms

How it works

Pregabalin binds to calcium channels in nerve cells, reducing the release of neurotransmitters that carry pain signals and cause seizures. By blocking these channels, the medication decreases abnormal nerve activity in both the brain and peripheral nervous system. This action helps control seizures, reduce nerve pain, and calm overactive neural pathways associated with anxiety.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Dizziness and drowsiness
  • Weight gain
  • Swelling in hands and feet
  • Blurred or double vision
  • Dry mouth
  • Difficulty concentrating
  • Increased appetite
  • Constipation

Serious side effects requiring immediate medical attention:

  • Severe allergic reactions with swelling of face, lips, or throat
  • Suicidal thoughts or behavior changes
  • Severe muscle weakness or pain
  • Heart problems or unusual bleeding
  • Severe skin reactions or blistering

Warnings and precautions

  • Pregnancy and breastfeeding: Pregabalin may cause harm to developing babies and passes into breast milk. Women should discuss risks and benefits with their healthcare provider before use during pregnancy or while nursing.
  • Kidney function: Dosage adjustments are necessary for patients with kidney disease, as the drug is primarily eliminated through the kidneys.
  • Mental health monitoring: Patients should be closely monitored for signs of depression, suicidal thoughts, or unusual mood changes, especially when starting treatment.
  • Dependence potential: Pregabalin has potential for abuse and dependence, particularly in individuals with a history of substance abuse.
  • Driving and machinery: The medication can cause dizziness and drowsiness, potentially impairing the ability to drive or operate machinery safely.

Interactions

Several medications and substances can interact with pregabalin:

  • Alcohol: Increases drowsiness and dizziness, potentially causing dangerous sedation
  • Opioid pain medications: Combined use may increase risk of respiratory depression and severe sedation
  • Benzodiazepines: Enhances sedative effects and may cause excessive drowsiness
  • Sleep medications: Compounds sedating effects and may impair cognitive function
  • Antihistamines: May increase drowsiness and reduce alertness
  • Blood pressure medications: ACE inhibitors may increase risk of swelling when combined with pregabalin
  • Diabetes medications: May enhance blood sugar-lowering effects, requiring glucose monitoring
  • Muscle relaxants: Can increase sedation and muscle weakness

Check interactions with the GMJ Interaction Checker

Dosage

Pregabalin dosages vary depending on the condition being treated and individual patient factors. For neuropathic pain, typical starting doses range from 150-300 mg daily, divided into two or three doses, with maximum doses up to 600 mg daily. For seizure control, doses typically start at 150 mg daily and may be increased to 600 mg daily based on response and tolerability. Fibromyalgia treatment usually begins with 75 mg twice daily, potentially increasing to 150-225 mg twice daily.

Dosage adjustments are required for patients with kidney impairment, and the medication should be tapered gradually when discontinuing to avoid withdrawal symptoms. Healthcare providers will determine the appropriate starting dose and adjustment schedule based on individual medical history, kidney function, and treatment response.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Pregabalin." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/pregabalin/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Five Distinct Diabetes Development Patterns Identified Years Before Diagnosis

European study of 18,567 adults reveals five distinct metabolic pathways leading to…

Coeliac Disease Linked to Increased Death Risk and Cancer in Major US Study

Major US study of 60,000+ patients reveals coeliac disease patients face 39%…

Paralympic Doctor Returns to Sport as Blind Athlete with Guide Runner

Dr Oscar, a former Paralympic competitor turned medical professional, returns to sport…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Gabapentin

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up